The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Sumant Lamba et al.|Nature Medicine|2021Cited by 599
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Cardiovascular Phenotype in HFpEF Patients With or Without DiabetesBrian R. Lindman, Margaret M. Redfield, Víctor G. Dávila‐Román et al.|Journal of the American College of Cardiology|2014Cited by 210
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risksAndrew Perry, Ravi V. Shah, Eric Farber‐Eger et al.|Nature Medicine|2024Cited by 35